TYRA

U.S. Stock Market Overview: U.S. stock futures are up, with Dow futures increasing by about 300 points, while several stocks, including Northrop Grumman, experienced significant declines in pre-market trading due to disappointing earnings reports.

Notable Stock Movements: Northrop Grumman shares fell 8.5% after missing earnings expectations, and other companies like USA Rare Earth and Halliburton also saw declines of over 5% in pre-market trading.

Calix, Inc. Financial Performance: Calix, Inc. shares surged 13.1% in pre-market trading after reporting first-quarter revenue of $220.24 million and adjusted earnings of 19 cents per share, both exceeding analyst expectations. The company also announced a $100 million increase in its stock buyback authorization.

Market Movements: Several stocks experienced significant pre-market trading fluctuations, with Gelteq Limited rising 329% and MKDWELL Tech Inc falling 43.5%. Other notable gainers included Standard Lithium Ltd and Mullen Automotive, while Outset Medical and National Energy Services Reunited Corp saw declines.

WaFd, Inc. Earnings Report: WaFd, Inc. shares rose 6.4% in pre-market trading after reporting a second-quarter GAAP EPS of 65 cents, exceeding estimates of 58 cents, with sales of $179.79 million surpassing expectations of $157.81 million.

Pre-Market Stock Movements: Several stocks experienced significant changes in pre-market trading, with notable gainers including Sharps Technology (up 73.6%) and Classover Holdings (up 61.2%), while Culp, Inc. saw a sharp decline of 56.2%.

Penguin Solutions Performance: Shares of Penguin Solutions, Inc. rose 2% to $18.41 in pre-market trading after the company reported better-than-expected second-quarter results and projected a 17% year-over-year net sales growth for FY25.

Stock Movements: Several stocks experienced significant changes in pre-market trading, with Protagenic Therapeutics gaining 173.2% and Kolibri Global Energy falling 41.7%, reflecting a mix of gains and losses across various companies.

Clinical Trials and Developments: Tyra Biosciences has received FDA clearance for three INDs to advance its lead drug, TYRA-300, into Phase 2 studies targeting intermediate risk non-muscle invasive bladder cancer, pediatric achondroplasia, and metastatic urothelial cancer, following promising interim results from earlier trials.

Financial Position: As of December 31, 2024, Tyra reported $341.4 million in cash and marketable securities, providing a financial runway through at least 2027, despite a net loss of $86.5 million for the year.

U.S. Stock Market Trends: U.S. stock futures are down, with the Dow futures dropping about 100 points; several stocks, including Incyte Corporation and USA Rare Earth, saw significant declines in pre-market trading following recent gains.

Notable Stock Movements: Incyte shares fell 15.3% after disappointing clinical trial results, while other companies like Affirm Holdings and Tyra Biosciences also experienced notable drops in their stock prices during pre-market trading.

Precision BioSciences Stock Surge: Shares of Precision BioSciences rose 10.8% to $5.58 in pre-market trading after the U.S. FDA cleared its investigational new drug application for PBGENE-HBV, aimed at treating chronic hepatitis B.

Pre-Market Trading Highlights: Several stocks experienced significant movements in pre-market trading, with notable gainers including NanoVibronix (up 42.3%) and Lytus Technologies (up 36.7%), while losers included Fold Holdings (down 18.8%) and Incyte Corporation (down 15.3%).

Upcoming Investor Conferences: Tyra Biosciences will participate in several investor conferences, including the Oppenheimer Healthcare Conference and TD Cowen Healthcare Conference, with presentations scheduled for February and March 2025.

Company Overview: Tyra Biosciences is a clinical-stage biotechnology firm focused on precision medicines targeting FGFR biology, with a pipeline that includes three clinical-stage programs and lead candidate TYRA-300, a selective FGFR3 inhibitor.

Appointment Announcement: Tyra Biosciences has appointed Adele Gulfo to its Board of Directors, bringing extensive experience in drug development and commercialization from her previous roles at major pharmaceutical companies like Pfizer and AstraZeneca.

Company Focus and Pipeline: Tyra Biosciences is focused on developing next-generation precision medicines targeting FGFR biology, with ongoing clinical programs including TYRA-300 for non-muscle invasive bladder cancer and other oncology-related therapies.

Tyra Biosciences Presentations: Tyra Biosciences announced the acceptance of two abstracts for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium, focusing on their investigational drugs TYRA-200 and TYRA-430 for treating advanced cancers with FGFR gene alterations.

Company Overview: Tyra Biosciences is a clinical-stage biotechnology company developing precision medicines targeting FGFR biology, with ongoing studies for multiple drug candidates aimed at various solid tumors.

Insider Trading Activity: Nina S Kjellson, a director at $TYRA, sold 3,993 shares for approximately $65,335, reducing her holdings to 3,707,420 shares. In the past six months, there have been 40 insider trades of $TYRA stock, predominantly sales.

Institutional Investor Movements: In the latest quarter, 50 institutional investors increased their positions in $TYRA stock while 31 reduced theirs, indicating mixed sentiment among institutional stakeholders.

New Appointment and Clinical Trial Initiation: Tyra Biosciences has appointed Dr. Erik Goluboff as SVP of Clinical Development to lead the Phase 2 clinical trial of TYRA-300 for low-grade, intermediate risk non-muscle invasive bladder cancer (NMIBC), with patient dosing expected to begin in Q2 2025.

TYRA-300 Overview: TYRA-300 is an investigational oral FGFR3-selective inhibitor designed to provide a better-tolerated treatment option for patients with IR NMIBC, aiming to address significant unmet medical needs in this patient population.

U.S. Stock Futures and Market Movements: U.S. stock futures rose this morning, with Dow futures increasing over 300 points; however, several stocks, including Neumora Therapeutics, experienced significant declines in pre-market trading.

Notable Stock Declines: Neumora Therapeutics shares plummeted 82.8% after disappointing study results, while other companies like SES AI Corporation and Tyra Biosciences also saw notable drops in their stock prices during pre-market trading.

Upcoming Investor Conferences: Tyra Biosciences, Inc. will participate in the Jefferies London Healthcare Conference from November 19-21 and the 36th Annual Piper Healthcare Conference from December 3-5, where CEO Todd Harris will engage in fireside chats and one-on-one investor meetings.

Company Overview: Tyra Biosciences is a clinical-stage biotechnology company focused on precision medicines targeting FGFR biology, with a pipeline that includes lead candidate TYRA-300 for cancer treatment and achondroplasia, as well as other investigational drugs for various cancers.

Earnings Report: Tyra Biosciences reported a Q3 GAAP EPS of -$0.41, which beat expectations by $0.06, and had $360.1 million in cash and marketable securities as of September 30, 2024.

Stock Performance: The company's stock fell 17% following the release of data from the TYRA-300 study, although it was raised to a "buy" rating by BofA prior to the data readout.

Insider Purchases at Reynolds Consumer Products: Director Rolf Stangl bought 7,207 shares of REYN for $27.25 each, totaling $196,378, marking his first purchase in the past year.

Tyra Biosciences Investment by CFO: Chief Financial Officer Alan Fuhrman purchased 9,500 shares of Tyra Biosciences for $16.00 each, amounting to $151,954, also his first purchase in the last twelve months.

Tyra Biosciences Options Activity: Tyra Biosciences Inc (TYRA) has seen significant options trading today, with 2,580 contracts representing about 66.4% of its average daily volume, particularly for the $25 strike call option expiring November 15, 2024.

Visa Inc Options Activity: Visa Inc (V) experienced high options trading volume of 32,795 contracts, equating to approximately 63.3% of its average daily volume, with notable activity in the $300 strike call option expiring November 01, 2024.

TYRA-300 Development: Tyra Biosciences has received FDA clearance for its investigational drug TYRA-300, an oral FGFR3-selective inhibitor, to begin a Phase 2 clinical trial (BEACH301) for children with achondroplasia, aiming to improve growth velocity and functional outcomes.

Clinical Trial Details: The BEACH301 study will enroll treatment-naïve children and those previously treated, assessing safety, tolerability, and growth changes over 12 months, with dosing expected to start in Q1 2025.

Clinical Data Release: Tyra Biosciences announced positive clinical proof-of-concept data for its FGFR3-selective inhibitor, TYRA-300, in patients with metastatic urothelial cancer during the SURF301 Phase 1/2 study, showing significant anti-tumor activity and a 100% disease control rate at doses ≥ 90 mg QD.

Safety Profile and Market Reaction: Preliminary safety results indicate that TYRA-300 is generally well-tolerated with minimal serious adverse events; however, Tyra Biosciences' stock fell by 18.4% following the announcement.

Stock Performance: Tyra Biosciences' stock fell 17% after the release of interim Phase 1/2 data for its drug candidate TYRA-300 aimed at treating metastatic urothelial cancer (mUC).

Clinical Study Update: The reported data from the study has raised concerns among investors, leading to the significant drop in stock price.